Raptor Pharmaceuticals Corp., a biopharmaceutical company focused on the development and commercialization of transformative treatments to treat rare diseases, has announced its participation in the European Respiratory Society (ERS) International Congress 2016.
While at the International Congress, Raptor will be presenting data from its detailed literature review and network meta-analysis of QUINSAIR, an inhalable version of levofloxacin, which compared its efficiency to other inhalable antibiotics used to treat lung infections known as chronic Pseudomonas aeruginosa in cystic fibrosis patients. The presentation on QUINSAIR data will take place at the London EXCEL during the ERS International Congress in London from Sept. 3-7.
The presentation is slated for Wednesday, Sept. 7 from 8:30 a.m. to 10:30 a.m. It will be part of the discussion on "Cystic fibrosis: inflammation, microbiology."
The presentation is entitled, "Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients with Cystic Fibrosis - Systematic Literature Review and Network Meta-Analysis."